Skip to main content
Cell Bio Human Tech Co., Ltd logo

Cell Bio Human Tech Co., Ltd — Investor Relations & Filings

Ticker · 318160 ISIN · KR7318160009 KO Professional, scientific and technical activities
Open in API
Filings indexed 146 across all filing types
Latest filing 2026-03-16 Proxy Solicitation & In…
Country KR South Korea
Listing KO 318160

About Cell Bio Human Tech Co., Ltd

http://cellbiohumantech.co.kr/en/

Cell Bio Human Tech Co., Ltd. is a company that develops and manufactures advanced nonwoven fabrics for the cosmetics sector. Utilizing cellulose reaction technology, the company produces specialized materials primarily for sheet masks and skincare pads. Its products, derived from various cellulose fibers, are engineered for differentiated performance, offering features such as high transparency and adhesion. The company provides customizable and eco-friendly fabric solutions, with key product lines including PT Cell and S Cell.

Recent filings

Filing Released Lang Actions
[기재정정]주주총회소집공고
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a formal 'Notice of General Meeting of Shareholders' (주주총회소집공고) for CellBioHumanTech. It details the meeting agenda, including financial statement approval, board changes, and capital reduction. It also includes management reports and governance information. While it contains information typically found in an Annual Report, the document itself is a formal notice and proxy-related material for the upcoming AGM, which fits the definition of a Proxy Solicitation & Information Statement (PSI) or AGM-R. Given the specific focus on the meeting agenda, voting items, and the formal notice structure, it is classified as a Proxy Solicitation & Information Statement.
2026-03-16 Korean
[기재정정]주요사항보고서(감자결정)
Share Issue/Capital Change Classification · 95% confidence The document is a 'Major Matter Report' (주요사항보고서) regarding a capital reduction (감자 결정) filed with the Korean financial authorities (Financial Services Commission/KRX). It details the amendment of the capital reduction schedule, including dates for the shareholder meeting, creditor objection period, and board resolution. Since this involves a change in capital structure (capital reduction/share cancellation), it falls under the 'Share Issue/Capital Change' category.
2026-03-16 Korean
[기재정정]주주총회소집결의
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a formal regulatory filing titled '주주총회소집결의' (Resolution for Convening a General Meeting of Shareholders) and a '정정신고' (Correction Report). It details the agenda, date, location, and specific items for an upcoming Annual General Meeting (AGM), including the appointment of an auditor and changes to business purposes. Since this document provides the specific agenda and materials for the meeting rather than just an announcement of the report's availability, it falls under the category of Proxy Solicitation & Information Statement (PSI) as it informs shareholders of the meeting details and requests their participation/votes.
2026-03-16 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a Korean regulatory filing titled '임원ㆍ주요주주 특정증권등 소유상황보고서' (Report on Ownership of Specific Securities by Executives and Major Shareholders). This is a standard disclosure required by the Financial Supervisory Service (FSS) in South Korea when a director or major shareholder changes their shareholding position. This corresponds to the 'Director's Dealing' category, which covers insider trades and changes in ownership by company executives.
2026-03-12 Korean
주주총회소집공고
AGM Information Classification · 95% confidence The document is a formal 'Notice of General Meeting of Shareholders' (주주총회소집공고) for CellBioHumanTech. It includes the meeting agenda, procedural details for voting, and extensive 'Management Reference' (경영참고사항) sections, which include board activity reports, financial summaries, and business overviews. This document is a standard proxy statement/information circular provided to shareholders to inform them of upcoming votes and company performance, which aligns with the 'Proxy Solicitation & Information Statement' category.
2026-03-11 Korean
기타주요경영사항 (유형자산 양수결정 철회)
Regulatory Filings Classification · 95% confidence The document is a regulatory filing from Cell Bio Human Tech regarding the cancellation of a previously announced acquisition of tangible assets (real estate). It details the reasons for the cancellation (legal restrictions on the seller's property) and the board's decision-making process. Since it is a specific corporate announcement regarding a material business event that does not fit into categories like M&A, dividends, or financial reports, it is classified as a general regulatory filing.
2026-03-04 Korean

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.